Fig. 2.

Classifier scores can be used to classify patients as immune-adaptive prevalent (IA-P) and immune-innate prevalent (IN-P) in the Burn trial. Patients were stratified to IA-P and IN-P groups based on baseline samples. The line marked by an asterisk shows that hydrocortisone treatment leads to a significant decrease of immune adaptive score of IA-P patients comparing baseline samples and 24 h post-treatment samples but not in placebo groups (P = 0.033). The blue and yellow lines represent the hydrocortisone and placebo groups, respectively.